A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC)

被引：0

作者：

Bajor, David L.

Lee, Ho Jun

Selfridge, J. Eva

Mohamed, Amr

Conces, Madison

Lumish, Melissa Amy

Chakrabarti, Sakti

Mahipal, Amit

Anderson, Erin E.

Donohue, Debbie

Tirumani, Sree Harsha

Dorth, Jennifer Anne

Henke, Lauren E.

Ocuin, Lee Mayer

Ammori, John Brian

Hardacre, Jeffrey

Winter, Jordan Michael

机构：

[1] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[2] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[3] Case Western Reserve Univ, Cleveland, OH USA

[4] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH USA

[5] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[6] Univ Hosp Seidman Canc Ctr, Dept Nursing, Cleveland, OH USA

[7] Univ Hosp Seidman Canc Ctr, Case Western Comprehens Canc Ctr, Dept Nursing, Cleveland, OH USA

[8] Univ Hosp, Case Med Ctr Seidman Canc Ctr, Cleveland, OH USA

[9] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Radiat Oncol, Cleveland, OH USA

[10] Univ Hosp Seidman Canc Ctr, Dept Surg, Cleveland, OH USA

[11] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[12] Dept Surg, Cleveland, OH USA

[13] Seidman Canc Ctr, Univ Hosp, Cleveland, OH USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4172

引用

页数：1